Myelin protein zero and its antibody in serum as biomarkers of n-hexane-induced peripheral neuropathy and neurotoxicity effects.

Xiaowei Jia; Qingjun Liu; Yanshu Zhang; Yufei Dai; Huawei Duan; Ping Bin; Yong Niu; Jie Liu; Liuzhen Zhong; Jisheng Guo; Xiaofeng Liu; Yuxin Zheng

Return

Myelin protein zero and its antibody in serum as biomarkers of n-hexane-induced peripheral neuropathy and neurotoxicity effects.

Author: Xiaowei JIA ¹ ; Qingjun LIU ² ; Yanshu ZHANG ³ ; Yufei DAI ¹ ; Huawei DUAN ¹ ; Ping BIN ¹ ; Yong NIU ¹ ; Jie LIU ⁴ ; Liuzhen ZHONG ⁵ ; Jisheng GUO ⁵ ; Xiaofeng LIU ⁵ ; Yuxin ZHENG ⁶
Author Information

1. Key Laboratory of Chemical Safety and Health, National Institute for Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
2. DSM Regulatory Affairs Department, DSM (China) Ltd., Beijing 100000, China.
3. College of Public Health, Hebei United University, Tangshan, Hebei 063009, China.
4. Suzhou Fifth People's Hospital, Suzhou, Jiangsu 215007, China.
5. Xixiang Health Inspection of Bao'an Distract, Shenzhen, Guangzhou, Guangdong 500000, China.
6. Key Laboratory of Chemical Safety and Health, National Institute for Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing 100050, China. Email: yxzheng@163bj.com.
Publication Type:Journal Article
MeSH: Adult; Antibodies; blood; immunology; Cross-Sectional Studies; Female; Hexanes; toxicity; Humans; Male; Myelin P0 Protein; blood; immunology; Peripheral Nervous System Diseases; blood; chemically induced; immunology; Young Adult
From: Chinese Medical Journal 2014;127(8):1536-1540
CountryChina
Language:English
Abstract:
BACKGROUNDChronic exposure to n-hexane can lead to peripheral neuropathy that no effective treatment regimen could be applied presently. This study investigated whether myelin protein zero (P0) protein and its antibody could be used to distinguish n-hexane intoxication and protect workers from peripheral neuropathy.
METHODSWe compared P0 protein and its antibody among three levels of n-hexane-exposed groups, which included 18 patients with n-hexane-induced peripheral neuropathy as case group, 120 n-hexane-exposed workers as n-hexaneexposed control group, and 147 non-hexane-exposed participants used as control group. ELISA method was applied to detect P0 protein and its antibody.
RESULTSP0 protein in serum was significantly higher in the case group and n-hexane-exposed control group in comparison with the control group (P < 0.01). Compared with the n-hexane-exposed control group, the case group also had significant increase of P0 protein (P < 0.01). After 6 months therapy, P0 protein was observed to decrease significantly in the case group (P < 0.01). The P0 antibody in serum was significantly higher in the n-hexane-exposed control group than in the control group (P < 0.01), but not significantly different between cases and controls.
CONCLUSIONSP0 antibodies in serum may be a short-term effect biomarker for n-hexane exposure. P0 protein in serum may be an early effective biomarker for peripheral nerve neuropathy and its biological limit value needs investigation in the future study.